Compare Charles River Laboratories Intl. Inc (CRL) vs Figs Inc (FIGS) Price & Performance

Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.

The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.

FIGS trades at $14.06, down 0.28% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth with 2025 revenue reaching $631.10M and net income of $34.25M, representing a 5.42% margin. Recent earnings beats and raised 2026 guidance indicate positive momentum, though valuation ratios remain elevated with a P/E of 45.39 and P/S of 4.02.

Wall Street maintains a bullish stance with 60% buy ratings and a $18.00 consensus price target, suggesting 28% upside potential. Key risks include execution challenges in international expansion and rich valuation multiples that require continued strong performance. The company's expanding customer base and international growth provide catalysts for future appreciation.